Last reviewed · How we verify
Cyclical neutropenia
Approved treatments
- Neupogen · University of Chicago
- Neupogen · Amgen
Filgrastim-aafi binds G-CSF receptors on hematopoietic cells, stimulating neutrophil proliferation, differentiation, and functional activation.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Cyclical neutropenia patent landscape — cliff calendar, originator estates, attackable patents
- Cyclical neutropenia treatment landscape brief
- Cyclical neutropenia treatment updates RSS
Frequently asked questions about Cyclical neutropenia
What drugs treat Cyclical neutropenia?
Tracked treatments include Neupogen.
What is the treatment for Cyclical neutropenia?
Standard treatment for Cyclical neutropenia includes Neupogen. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Cyclical neutropenia patent cliff · Cyclical neutropenia CI report
- Treatment: Neupogen · University of Chicago
- Treatment: Neupogen · Amgen
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing